Blueprint Medicines Corp (BPMC) concluded trading on Thursday at a closing price of $129.33, with 5.98 million shares of worth about $773.9 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 44.44% during that period and on July 10, 2025 the price saw a gain of about 0.61%. Currently the company’s common shares owned by public are about 64.56M shares, out of which, 62.27M shares are available for trading.
Stock saw a price change of 0.88% in past 5 days and over the past one month there was a price change of 1.06%. Year-to-date (YTD), BPMC shares are showing a performance of 11.18% which increased to 48.28% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $73.04 but also hit the highest price of $128.78 during that period. The average intraday trading volume for Blueprint Medicines Corp shares is 3.13 million. The stock is currently trading 0.81% above its 20-day simple moving average (SMA20), while that difference is up 12.55% for SMA50 and it goes to 31.38% higher than SMA200.
Blueprint Medicines Corp (NASDAQ: BPMC) currently have 64.56M outstanding shares and institutions hold larger chunk of about 106.61% of that.
The stock has a current market capitalization of $8.36B and its 3Y-monthly beta is at 0.94. It has posted earnings per share of -$2.46 in the same period. It has Quick Ratio of 2.75 while making debt-to-equity ratio of 2.08. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BPMC, volatility over the week remained 0.22% while standing at 0.23% over the month.
Stock’s fiscal year EPS is expected to rise by 34.48% while it is estimated to increase by 231.01% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wedbush on June 02, 2025 offering a Neutral rating for the stock and assigned a target price of $129 to it. Coverage by Morgan Stanley stated Blueprint Medicines Corp (BPMC) stock as an Equal-weight in their note to investors on March 20, 2025, suggesting a price target of $100 for the stock. On March 18, 2025, Wolfe Research Initiated their recommendations, while on March 17, 2025, Jefferies Initiated their ratings for the stock with a price target of $135. Stock get a Sector outperform rating from Scotiabank on March 07, 2025.
